Clinical Edge Journal Scan

Gastric cancer: Sarcopenic obesity is a risk factor for poorer outcomes after gastrectomy


 

Key clinical point: The presence of sarcopenic obesity (SO) increases the risk for severe postoperative complications and worse survival outcomes in patients who have undergone gastrectomy for gastric cancer.

Major finding: SO was associated with an increased risk for serious Clavien-Dindo complications grade >IIIb/IV (odds ratio 2.82; P = .028) and worse overall survival (adjusted hazard ratio 0.45; P = .026) after gastrectomy.

Study details: This single-center retrospective study included 190 patients with gastric cancer who had undergone curative-intent gastrectomy, of which 40 patients had SO.

Disclosures: This study did not report the source of funding. The authors declared no conflicts of interest.

Source: Juez LD et al. Impact of sarcopenic obesity on long-term cancer outcomes and postoperative complications after gastrectomy for gastric cancer. J Gastrointest Surg. 2022 (Nov 2). Doi: 10.1007/s11605-022-05492-w

Recommended Reading

CRC: Severe inflammatory response in early postoperative period increases risk for recurrence
MDedge Hematology and Oncology
Excellent prognostic ability of neutrophil-to-lymphocyte ratio in CRC liver metastasis
MDedge Hematology and Oncology
mCRC: Triplet+bevacizumab offers survival advantage even in patients with bone metastasis
MDedge Hematology and Oncology
Comparative analysis of total neoadjuvant therapy vs standard therapy in LARC
MDedge Hematology and Oncology
ctDNA detection following curative surgery for colorectal cancer predicts poor prognosis
MDedge Hematology and Oncology
Bemarituzumab shows promising efficacy in patients with FGFR2b-selected gastric cancer
MDedge Hematology and Oncology
Gastric ulcer increases the risk for gastric cancer
MDedge Hematology and Oncology
Preoperative D-dimer-to-albumin ratio: A biomarker for long-term prognosis in gastric cancer
MDedge Hematology and Oncology
Disease progression pattern linked with poor prognosis in advanced gastric cancer patients on nivolumab
MDedge Hematology and Oncology
Intestinal metaplasia before H. pylori eradication hints at post-eradication gastric cancer surveillance
MDedge Hematology and Oncology